Juvenescence

Juvenescence is longevity's consolidator — a holding-company and capital hub that aggregates aging assets under one structure rather than betting on a single mechanism, a diversification that matters in a field where individual programs routinely fail. Co-founded in 2016 by veteran biotech investor Jim Mellon with Greg Bailey and Declan Doogan, it has assembled a portfolio spanning oral small molecules (a PAI-1 inhibitor, a CD38 inhibitor, an exogenous-ketone program), biologics, and neurodegeneration, historically including AgeX-linked assets, and roughly $325M raised across rounds. The 2025 strategic partnership with Abu Dhabi's M42 is the pivotal validation: M42 invested at a valuation reportedly north of $550M and led the $76M first close of a Series B-1, plugging Juvenescence into sovereign-scale healthcare capital and Abu Dhabi's clinical-development infrastructure precisely as Gulf states pour money into longevity as a national strategy. Layering the May 2025 acquisition of AI drug-discovery firm Ro5 — whose biomedical knowledge graph spans over 85 million nodes and roughly 400 million relationships — onto that capital gives Juvenescence in-house machine-learning target and molecule design across the whole portfolio. The holding-company model spreads risk, the M42 relationship de-risks funding and gives Middle East market access, and Mellon's investor network and consolidator instincts position Juvenescence to keep acquiring undervalued aging assets in a down market — a diversified way to own the sector rather than one shot on goal.